{"schema_version":"1.0","type":"article","title":"痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度","url":"https://drugnews.com.tw/articles/2026-07-10-fda-nasp.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-10-fda-nasp.md","lang":"zh-Hant","date":"2026-07-10","publish_at":"2026-07-10T09:49:00+08:00","updated_at":"2026-07-10","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","FDA","NASP","Sobi","CMC","委託製造","製造品質","難治性痛風","URAT1","臨床數據","生技投資","台灣生技"],"summary":"FDA 並未指出影響 NASP 核准可能性的臨床療效或安全性問題，真正要求補強的是 CMC 控制策略與委託製造設施缺失。這封 CRL 提醒投資人：越接近上市，製造可信度越是藥品價值的一部分。","key_points":[],"facts":[],"sections":["01｜NASP 是什麼？一款想解決尿酸酶免疫原性的痛風療法","02｜為什麼這個市場還有空間？因為已上市療法仍有不便與免疫原性問題","03｜FDA 這次打回票，重點不是療效，而是 CMC","04｜NASP 走到這一步，反而說明痛風高階療法不是沒有價值","05｜這件事對生技股的提醒：不要只看臨床，還要看誰能把產品做出來","06｜台灣可以看什麼？從 URAT1 到 Febuxostat，先看高尿酸用藥鏈","結語｜FDA 這封 CRL，真正打醒的是製造端風險"],"references":[{"title":"Sobi","source":"[Sobi receives Complete Response Letter from FDA for NASP, nanoencapsulated sirolimus plus pegadricase]","date":"","url":"https://www.sobi.com/en/press-releases/sobi-receives-complete-response-letter-fda-nasp-nanoencapsulated-sirolimus-plus-pegadricase-2465072"},{"title":"ClinicalTrials.gov","source":"[DISSOLVE I, NCT04513366]","date":"","url":"https://clinicaltrials.gov/study/NCT04513366"},{"title":"ClinicalTrials.gov","source":"[DISSOLVE II, NCT04596540]","date":"","url":"https://clinicaltrials.gov/study/NCT04596540"},{"title":"ClinicalTrials.gov","source":"[COMPARE, NCT03905512]","date":"","url":"https://clinicaltrials.gov/study/NCT03905512"},{"title":"ClinicalTrials.gov","source":"[AR882-301, NCT06846515]","date":"","url":"https://clinicaltrials.gov/study/NCT06846515"},{"title":"ClinicalTrials.gov","source":"[AR882-302, NCT06439602]","date":"","url":"https://clinicaltrials.gov/study/NCT06439602"},{"title":"DailyMed","source":"[KRYSTEXXA（pegloticase）injection label]","date":"","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e566303-d93a-4130-b764-25749829aa95"},{"title":"衛生福利部食品藥物管理署","source":"[未註銷藥品許可證資料集]","date":"","url":"https://data.gov.tw/dataset/9123"},{"title":"PubMed","source":"[Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor]","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/41113711/"},{"title":"PubMed","source":"[Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs]","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/40169562/"}],"images":[{"alt":"NASP 以奈米包封 sirolimus 搭配 pegadricase，兼顧免疫調節與尿酸分解","url":"https://drugnews.com.tw/assets/articles/fda-nasp/facebook-02.png"},{"alt":"NASP 的 FDA CRL 聚焦 CMC 與委託製造缺失，而非臨床療效或安全性","url":"https://drugnews.com.tw/assets/articles/fda-nasp/facebook-01.png"},{"alt":"NASP 從第三期臨床、BLA 審查走到 FDA CRL 的開發路徑","url":"https://drugnews.com.tw/assets/articles/fda-nasp/facebook-03.png"},{"alt":"台灣高尿酸與痛風用藥鏈：URAT1、尿酸生成抑制與難治性高階療法","url":"https://drugnews.com.tw/assets/articles/fda-nasp/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/fda-nasp/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-10）。痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度。https://drugnews.com.tw/articles/2026-07-10-fda-nasp.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-10-fda-nasp-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}